<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2284">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860857</url>
  </required_header>
  <id_info>
    <org_study_id>2017-3832</org_study_id>
    <secondary_id>R01AG053555-02</secondary_id>
    <nct_id>NCT03860857</nct_id>
  </id_info>
  <brief_title>MRI and PET Biomarkers for Cognitive Decline in Older Adults</brief_title>
  <official_title>MRI and PET Biomarkers for Cognitive Decline in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to understand the factors that underlie changes in&#xD;
      thinking and memory with increasing age. The investigators will test the usefulness of MRI,&#xD;
      PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive&#xD;
      decline. An addendum to this study includes additional PET scans to examine the relationship&#xD;
      between tau protein in the brain and cognitive decline. Tau is a protein that is known to&#xD;
      form tangles in the areas of the brain important for memory, and these tau tangles are a&#xD;
      hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation&#xD;
      in the brain using an investigational drug called MK-6240, which is a radio tracer that gets&#xD;
      injected prior to a positron emission tomography (PET) scan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates the relationship between Alzheimer's disease (AD) pathology, brain&#xD;
      structure and function, as well as cognition in non-demented older adults. The goal is to&#xD;
      develop a more complete understanding of the factors that lead to cognitive decline in the&#xD;
      elderly and progression to AD. The investigators will enroll 200 cognitively intact adults&#xD;
      between the ages of 60-85 years old from the UCI Alzheimer's Disease Research Center or&#xD;
      directly from the local community. Study procedures will include: 1) PET amyloid scans with&#xD;
      Amyvidâ„¢ radiotracer (florbetapir-F18) and PET tau scans with [18F]MK6240 radiotracer; 2)&#xD;
      High-resolution structural, functional, and diffusion MRI; and 3) Cognitive examinations. The&#xD;
      investigators will track cognitive outcomes through longitudinal monitoring. Amyloid imaging&#xD;
      will only be conducted once in the study at baseline, and MRI and tau PET imaging will be at&#xD;
      baseline and Year 1. The investigators aim to identify the best combination of tests for&#xD;
      predicting longitudinal cognitive/clinical decline. The proposed study will significantly&#xD;
      inform the understanding of cognitive decline in the aging brain and allow investigators to&#xD;
      better define preclinical AD and make recommendations for future intervention trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 22, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants will complete the same study procedures, including the tau PET scans with investigational radio tracer 18F-MK6240. The arms define the age range and APOE status of the participants, with each having their own enrollment target.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinical Dementia Rating - Sum of Box Score</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>A measure of cognitive/clinical decline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lure discrimination index - objects</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of performance on the object pattern separation task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lure discrimination index - spatial</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of performance on the spatial pattern separation task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lure discrimination index - temporal</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of performance on the temporal pattern separation task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in entorhinal cortical thickness</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of structural decline on MRI scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perforant path integrity</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of structural connectivity decline on MRI scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tau spatial distribution - advancing Braak stage</measure>
    <time_frame>Years 4 and 5 of the grant</time_frame>
    <description>Key measure of tau spatial spread on tau PET scans</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Age 60-65 ApoE e4+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 60-65 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 66-70 ApoE e4-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 66-70 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 66-70 ApoE e4+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 66-70 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 71-75 ApoE e4-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 71-75 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 71-75 ApoE e4+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 71-75 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 76-80 ApoE e4-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 76-80 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 76-80 ApoE e4+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 76-80 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 81+ ApoE e4-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 81-85 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 81+ ApoE e4+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort are between the ages of 81-85 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Amyloid PET scan</intervention_name>
    <description>Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18</description>
    <arm_group_label>Age 60-65 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4-</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4+</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4-</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4+</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4-</arm_group_label>
    <arm_group_label>Age 81+ ApoE e4+</arm_group_label>
    <arm_group_label>Age 81+ ApoE e4-</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tau PET scan using MK-6240</intervention_name>
    <description>Tau Positron Emission Tomography scan using radio tracer MK-6240</description>
    <arm_group_label>Age 60-65 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4-</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4+</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4-</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4+</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4-</arm_group_label>
    <arm_group_label>Age 81+ ApoE e4+</arm_group_label>
    <arm_group_label>Age 81+ ApoE e4-</arm_group_label>
    <other_name>tau PET</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Neurocognitive testing</intervention_name>
    <description>A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.</description>
    <arm_group_label>Age 60-65 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4-</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4+</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4-</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4+</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4-</arm_group_label>
    <arm_group_label>Age 81+ ApoE e4+</arm_group_label>
    <arm_group_label>Age 81+ ApoE e4-</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.</description>
    <arm_group_label>Age 60-65 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4+</arm_group_label>
    <arm_group_label>Age 66-70 ApoE e4-</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4+</arm_group_label>
    <arm_group_label>Age 71-75 ApoE e4-</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4+</arm_group_label>
    <arm_group_label>Age 76-80 ApoE e4-</arm_group_label>
    <arm_group_label>Age 81+ ApoE e4+</arm_group_label>
    <arm_group_label>Age 81+ ApoE e4-</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 60 and above;&#xD;
&#xD;
          2. Speaks fluent English or Spanish;&#xD;
&#xD;
          3. Visual and auditory acuity adequate for neuropsychological and computerized testing;&#xD;
&#xD;
          4. Good general health with no disease(s) expected to interfere with the study;&#xD;
&#xD;
          5. Willing and able to participate for the duration of the study and in all study&#xD;
             procedures including MRI and PET;&#xD;
&#xD;
          6. Normal cognition defined as a Clinical Dementia Rating of 0 and a Mini-Mental State&#xD;
             Examination score of 27 or higher.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant co-morbid neurologic disease such as Parkinson's disease, multiple&#xD;
             sclerosis, brain cyst, tumor or aneurysm;&#xD;
&#xD;
          2. Major health conditions such as uncontrolled diabetes mellitus, uncontrolled&#xD;
             hypertension, nutritional deficiency or uncontrolled thyroid disease;&#xD;
&#xD;
          3. Significant psychiatric disorders such as schizophrenia, bipolar disorder, anxiety&#xD;
             disorder, major depressive disorder, or attention-deficit hyperactivity disorder;&#xD;
&#xD;
          4. ADRC consensus diagnosis of dementia or mild cognitive impairment;&#xD;
&#xD;
          5. Cognitive impairment when tested at baseline (defined as a score on any&#xD;
             neuropsychological test of 1.5 SDs or more outside the age norm);&#xD;
&#xD;
          6. Alcohol or substance abuse or dependence within the past 2 years (DSM-IV criteria);&#xD;
&#xD;
          7. MRI contraindications, e.g. pacemakers, aneurysm clips, artificial heart valves, ear&#xD;
             implants, metal fragments or foreign objects in the eyes, skin or body. Females who&#xD;
             are pregnant or trying to get pregnant are also excluded;&#xD;
&#xD;
          8. PET contraindications, e.g. significant prior radiation exposure and pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Yassa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liv C McMillan, BS, CCRP</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alyssa Harris, BA</last_name>
    <phone>949-824-0904</phone>
    <email>beacon@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novelle Meza, BS</last_name>
    <phone>949-824-5049</phone>
    <email>njmeza@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Harris, BA</last_name>
      <phone>949-824-0904</phone>
      <email>beacon@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Novelle Meza, BS</last_name>
      <phone>949-824-5049</phone>
      <email>njmeza@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael A Yassa, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://beacon.bio.uci.edu</url>
    <description>BEACoN (Biomarker Exploration in Aging, Cognition, and Neurodegeneration) study website</description>
  </link>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>October 18, 2022</last_update_submitted>
  <last_update_submitted_qc>October 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Michael Yassa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer disease</keyword>
  <keyword>cognitive impairment</keyword>
  <keyword>mild cognitive impairment</keyword>
  <keyword>biomarker</keyword>
  <keyword>MRI</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

